Ultragenyx Pharmaceutical | RARE - Cost Of Sales


Ultragenyx Pharmaceutical reported $30M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 28.32M 3.52M Jun/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Alnylam Pharmaceuticals USD 298.45M 87.33M Jun/2026
BioCryst Pharmaceuticals USD 3.84M 5.68M Jun/2026
BioMarin Pharmaceutical USD 276.29M 76.8M Jun/2026
Insmed USD 69.29M 19.79M Jun/2026
Ionis Pharmaceuticals USD 2.74M 261K Jun/2026
Karyopharm Therapeutics USD 1.34M 139K Mar/2026
Kyowa Hakko Kirin JPY 39.13B 6.13B Jun/2026
MacroGenics USD 9.53M 585K Mar/2026
Moderna USD 93M 862M Jun/2026
Neurocrine Biosciences USD 39.4M 25.6M Jun/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 576.5M 92.9M Jun/2026
Sarepta Therapeutics USD 150.1M 40.64M Jun/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vertex Pharmaceuticals USD 489.2M 96.4M Jun/2026